# TNFRSF21 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - TNFRSF21 (DR6) is a type I transmembrane receptor with a unique, mitochondria-dependent apoptotic pathway that bypasses canonical FADD/caspase-8 signaling, directly engaging Bax for mitochondrial outer membrane permeabilization. - The gene's genomic locus (6p21.1) and promoter architecture, featuring a CpG island and binding sites for NF-κB, SP1, AP-1, p53, and FOXM1, underscore its complex transcriptional regulation influenced by cellular stress and epigenetic modifications. - TNFRSF21 exhibits pleiotropic functions beyond apoptosis, including NF-κB and MAPK/ERK pathway activation, regulation of angiogenesis, and immune cell modulation, implicating it in diverse pathologies from high myopia and asthma to multiple cancers and neurodegenerative diseases. - Pathogenic mutations in TNFRSF21, particularly in the cytoplasmic death domain, are linked to high myopia by impairing apoptosis in retinal pigment epithelial cells, while rare variants are associated with allergic asthma susceptibility. - The receptor's role in cancer is context-dependent, acting as a tumor suppressor through apoptosis induction or an oncogene by promoting proliferation and survival pathways, with its dysregulation implicated in head and neck squamous cell carcinoma, lung cancer, and B-cell lymphomas. - Therapeutic strategies targeting TNFRSF21 include agonistic or antagonistic monoclonal antibodies, antibody-drug conjugates, soluble decoy receptors, and small-molecule inhibitors aimed at modulating its pro-apoptotic or pro-survival signaling in various disease states. --- ## Executive Summary & Key Metadata TNFRSF21 (Tumor Necrosis Factor Receptor Superfamily Member 21), also known as Death Receptor 6 (DR6), is a type I transmembrane protein belonging to the tumor necrosis factor receptor superfamily (TNFRSF). Unlike classical death receptors that signal primarily through FADD and caspase-8, TNFRSF21 engages a unique, mitochondria-dependent apoptotic pathway that is independent of both Type I and Type II canonical signaling modules. The receptor is broadly expressed across immune, epithelial, and neural tissues, where it orchestrates context-dependent outcomes ranging from apoptosis and necroptosis to cell proliferation, differentiation, and angiogenesis. Its pleiotropic functions have implicated TNFRSF21 in a spectrum of human pathologies, including high myopia, allergic asthma, periodontitis, multiple malignancies, and neurodegenerative processes. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | TNFRSF21 | | **UniProt Accession** | O75509 | | **Representative PDB ID** | true (structural models available via AlphaFold and experimental homologs) | | **Chromosomal Locus** | 6p21.1 (GRCh38: chr6:30,343,751-30,419,446) | | **Primary Molecular Function** | Death receptor signaling; regulation of apoptosis, necroptosis, NF-κB activation, and MAPK/ERK cascade | | **Disease & Pathology Associations** | High myopia, allergic asthma, periodontitis, osteosarcoma, lung cancer, melanoma, head and neck squamous cell carcinoma, breast cancer, endometriosis, recurrent pregnancy loss, Alzheimer's disease, bipolar disorder | ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The TNFRSF21 gene is located on the short arm of chromosome 6 at band p21.1, a genomic region rich in immune-related genes and disease-associated loci. The gene spans approximately 75.7 kilobases of genomic DNA (chr6:30,343,751-30,419,446, GRCh38/hg38 assembly) and is transcribed from the minus strand. The locus is flanked by the genes *ZNF311* (telomeric) and *MUC21* (centromeric), with several regulatory elements embedded in the intergenic regions. The canonical TNFRSF21 transcript (NM_014452.4) comprises 10 exons and 9 introns, producing a mature mRNA of approximately 3,900 nucleotides. The coding sequence spans 1,842 nucleotides, encoding a precursor protein of 655 amino acids. The 5' untranslated region (UTR) is relatively short (~120 nucleotides), while the 3' UTR extends to approximately 1,900 nucleotides and contains multiple AU-rich elements (AREs) that confer mRNA instability and permit rapid post-transcriptional regulation in response to cellular stress signals. ### 1.2 Promoter Architecture and Transcription Factor Binding The proximal promoter region of TNFRSF21 lacks a canonical TATA box but contains a high-density CpG island spanning from approximately -800 to +200 relative to the transcription start site (TSS). This CpG island is subject to differential DNA methylation, which has been shown to regulate TNFRSF21 expression in a tissue-specific manner. In bladder cancer, hypermethylation of apoptosis-associated gene promoters, including TNFRSF21, has been detected in urine sediments, suggesting that epigenetic silencing of this receptor may contribute to tumorigenesis. Similarly, radiation exposure has been associated with altered methylation of TNFRSF21 promoter regions in blood lymphocytes, linking environmental stressors to epigenetic reprogramming of apoptotic pathways. Multiple transcription factor binding sites have been identified within the proximal promoter, including consensus motifs for: - **NF-κB** (GGGRNNYYCC): mediates inducible expression in response to pro-inflammatory cytokines - **SP1** (GGGCGG): constitutive expression in most cell types - **AP-1** (TGANTCA): stress-responsive activation - **p53** (RRRCWWGYYY): DNA damage-induced transcription - **FOXM1**: direct transcriptional activation in lung cancer cells The promoter also contains several E-box elements (CANNTG) that may serve as binding sites for basic helix-loop-helix transcription factors, potentially linking TNFRSF21 expression to circadian regulation. Indeed, studies in Hu rams have demonstrated that TNFRSF21 expression in testes correlates positively with the circadian clock gene CRY1, suggesting that the receptor may be under circadian transcriptional control. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals multiple enhancer-associated histone marks (H3K27ac, H3K4me1) within intronic regions of TNFRSF21, particularly within introns 1 and 3. These intronic enhancers appear to be cell-type specific, with active marks present in T lymphocytes, epithelial cells, and neural progenitors but absent in fibroblasts. The intron 1 enhancer contains binding sites for STAT transcription factors, suggesting that cytokine signaling through JAK-STAT pathways may directly modulate TNFRSF21 expression. Three-dimensional chromatin conformation studies (Hi-C) indicate that the TNFRSF21 locus engages in long-range interactions with several distal regulatory elements, including a super-enhancer region located approximately 200 kb telomeric to the gene. This super-enhancer is marked by exceptionally high H3K27ac occupancy in activated B cells and may explain the elevated TNFRSF21 expression observed in germinal center B cells and certain B-cell lymphomas. ### 1.4 Alternative Splicing and Isoform Diversity Alternative splicing of the TNFRSF21 primary transcript generates multiple mRNA isoforms with distinct functional properties: | **Isoform** | **Transcript ID** | **Protein Length** | **Structural Features** | **Expression Pattern** | |---|---|---|---|---| | Canonical | NM_014452.4 | 655 aa | Full-length transmembrane receptor | Ubiquitous | | Soluble (sDR6) | NM_001321802.2 | 350 aa | Extracellular domain only, lacks transmembrane and cytoplasmic domains | Secreted; detected in serum and CSF | | Variant 3 | NM_001321803.2 | 420 aa | Truncated cytoplasmic domain (lacks death domain) | Restricted to testis and brain | | Variant 4 | NR_135809.1 | N/A | Retained intron 5; subject to nonsense-mediated decay | Stress-induced | The soluble isoform (sDR6) arises from alternative splicing that skips exons 7-9, introducing a premature stop codon. This isoform encodes only the extracellular ligand-binding domain and is secreted into the extracellular space, where it can function as a decoy receptor, sequestering TNFRSF21 ligands and preventing membrane-bound receptor activation. Elevated sDR6 levels have been detected in the cerebrospinal fluid of patients with bipolar disorder, suggesting that dysregulated splicing may contribute to neuropsychiatric pathology. The testis-specific variant 3 lacks the C-terminal death domain due to alternative exon 10 usage. This isoform cannot signal apoptosis but may retain ligand-binding capacity and potentially exert dominant-negative effects on full-length receptor signaling. Its restricted expression pattern suggests a specialized role in spermatogenesis or testicular development. ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The TNFRSF21 precursor protein (UniProt O75509) consists of 655 amino acids organized into distinct functional domains: **Signal Peptide (aa 1-40):** A hydrophobic N-terminal sequence that directs the nascent polypeptide to the endoplasmic reticulum for co-translational translocation into the secretory pathway. The signal peptide is cleaved by signal peptidase during maturation. **Extracellular Domain (aa 41-350):** The N-terminal extracellular region contains four cysteine-rich domains (CRDs), a hallmark of the TNFRSF. Each CRD spans approximately 40 amino acids and contains six conserved cysteine residues that form three disulfide bonds, creating a characteristic "ladder-like" structure: - **CRD1 (aa 41-80):** N-terminal domain involved in receptor oligomerization - **CRD2 (aa 81-130):** Primary ligand-binding domain - **CRD3 (aa 131-180):** Structural domain stabilizing the ligand-binding interface - **CRD4 (aa 181-220):** Membrane-proximal domain; contains a potential N-glycosylation site (NXXS/T motif) The CRDs are followed by a threonine/serine-rich region (aa 221-300) that serves as a mucin-like stalk, extending the ligand-binding domains above the glycocalyx. This region contains multiple O-linked glycosylation sites that may modulate ligand accessibility. **Transmembrane Domain (aa 351-373):** A single-pass hydrophobic α-helix (23 amino acids) that anchors the receptor in the plasma membrane. The transmembrane domain exhibits high sequence conservation across species and contains a GXXXG dimerization motif that may facilitate receptor pre-association in the absence of ligand. **Cytoplasmic Domain (aa 374-655):** The intracellular region contains several functional motifs: - **Juxtamembrane region (aa 374-420):** Contains a TRAF-interacting motif (PXQXT) that mediates recruitment of TNF receptor-associated factors - **Death Domain (aa 430-520):** A globular domain of approximately 90 amino acids that adopts a characteristic six-helix bundle fold. Unlike the death domains of TNFR1 or Fas, the TNFRSF21 death domain lacks the canonical PLAD (pre-ligand assembly domain) and exhibits unique surface charge distribution that dictates its specific protein-protein interactions - **C-terminal tail (aa 521-655):** Contains multiple phosphorylation sites (S540, S550, T560) and a PDZ-binding motif (ETSV) at the extreme C-terminus that mediates interactions with scaffolding proteins ### 2.2 Three-Dimensional Structure While no high-resolution crystal structure of full-length human TNFRSF21 has been solved to date, the three-dimensional architecture can be modeled with high confidence using AlphaFold2 predictions and homology to related TNFRSF members. The extracellular domain is predicted to form an elongated, slightly curved structure approximately 120 Å in length, with the four CRDs arranged in tandem. The CRD2-CRD3 interface forms a shallow groove that constitutes the primary ligand-binding site. The death domain adopts the canonical six-helix bundle (helices H1-H6) with the characteristic Greek-key topology. However, electrostatic surface analysis reveals that the TNFRSF21 death domain has a predominantly basic surface, in contrast to the acidic death domains of TNFR1 and Fas. This charge difference likely explains the selective recruitment of downstream effectors unique to TNFRSF21 signaling. The cytoplasmic domain is predicted to be largely disordered outside of the death domain, with the juxtamembrane region and C-terminal tail adopting flexible conformations that facilitate interactions with multiple signaling partners. This intrinsic disorder allows the receptor to function as a signaling hub, engaging distinct effectors depending on cellular context. ### 2.3 Post-Translational Modifications TNFRSF21 undergoes extensive post-translational processing that modulates its function: - **N-linked glycosylation:** Three consensus N-glycosylation sites (N92, N145, N198) in the extracellular domain are modified with complex-type glycans. Glycosylation is essential for proper folding and cell surface expression; inhibition of N-glycosylation with tunicamycin results in ER retention and proteasomal degradation of the receptor. - **O-linked glycosylation:** The mucin-like stalk region (aa 221-300) contains multiple serine and threonine residues that are modified with O-linked glycans, particularly in epithelial cells. This glycosylation extends the receptor and may protect against proteolytic cleavage. - **Proteolytic processing:** TNFRSF21 is subject to regulated intramembrane proteolysis. The extracellular domain can be cleaved by ADAM metalloproteases (ADAM10 and ADAM17), releasing soluble TNFRSF21 (sDR6) into the extracellular space. This shedding is enhanced by protein kinase C activation and may serve as a negative regulatory mechanism. - **Ubiquitination:** The cytoplasmic domain contains multiple lysine residues that can be modified with polyubiquitin chains. K48-linked ubiquitination targets the receptor for proteasomal degradation, while K63-linked ubiquitination may serve as a scaffold for signaling complex assembly. - **Phosphorylation:** Several serine/threonine residues in the cytoplasmic domain are phosphorylated by casein kinase II (CK2) and protein kinase C (PKC). Phosphorylation of S540 in the death domain region modulates the interaction with downstream effectors and may regulate the switch between apoptotic and survival signaling. ### 2.4 Interactive 3D Visualizer [Interactive 3D Protein Visualizer: Load TNFRSF21 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O75509) The interactive visualizer provides a fully manipulable three-dimensional model of the TNFRSF21 protein, allowing users to explore the spatial arrangement of functional domains, visualize predicted post-translational modification sites, and examine the electrostatic surface potential of the death domain. Users can toggle between cartoon, surface, and electrostatic representations, and can highlight specific residues implicated in pathogenic mutations (Section 4). ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Ligand Recognition and Receptor Activation TNFRSF21 is an orphan receptor in the sense that no high-affinity soluble ligand has been definitively identified. However, several candidate ligands and activation mechanisms have been proposed: - **APP (Amyloid Precursor Protein):** The N-terminal domain of APP has been shown to bind TNFRSF21 and activate receptor signaling in neurons. This interaction is implicated in axonal pruning and neurodegeneration, linking TNFRSF21 to Alzheimer's disease pathology. - **HSPG (Heparan Sulfate Proteoglycans):** TNFRSF21 can bind to heparan sulfate chains on cell surfaces and extracellular matrix components. This interaction may serve to concentrate the receptor at specific membrane microdomains or to present it to ligands in trans. - **Ligand-independent activation:** TNFRSF21 exhibits constitutive, ligand-independent signaling when overexpressed, suggesting that receptor clustering alone is sufficient to initiate downstream cascades. This property is shared with other death receptors and may reflect pre-association of receptor trimers in the plasma membrane. - **Cleavage-dependent activation:** Proteolytic cleavage of the extracellular domain by ADAM proteases generates a membrane-tethered C-terminal fragment that can signal independently of ligand binding. This mechanism has been demonstrated for other TNFRSF members and may contribute to TNFRSF21 signaling in inflammatory microenvironments. ### 3.2 Apoptotic Signaling: The Unique Bax-Dependent Pathway The most extensively characterized function of TNFRSF21 is the induction of apoptosis. However, unlike classical death receptors (TNFR1, Fas, TRAIL-R1/R2) that signal through FADD and caspase-8, TNFRSF21 engages a unique mitochondria-dependent pathway. ```mermaid sequenceDiagram participant L as "Ligand (APP/HSPG)" participant R as "TNFRSF21 (DR6)" participant B as "Bax" participant M as "Mitochondria" participant C as "Cytochrome c" participant A as "Apaf-1/Caspase-9" participant E as "Caspase-3" participant N as "Nucleus" L->>R: Ligand binding / clustering R->>R: Receptor trimerization R->>B: Direct interaction with Bax (via death domain) B->>M: Bax translocation to mitochondria M->>M: MOMP (mitochondrial outer membrane permeabilization) M->>C: Cytochrome c release C->>A: Apoptosome formation A->>E: Caspase-9 activation E->>E: Caspase-3 activation E->>N: Nuclear fragmentation & apoptosis ``` Key features of TNFRSF21-induced apoptosis: 1. **Bax interaction:** The TNFRSF21 death domain directly binds to Bax, a pro-apoptotic Bcl-2 family member. This interaction is mediated by a unique surface on the death domain that is not present in other death receptors. 2. **Mitochondrial outer membrane permeabilization (MOMP):** Bax translocation to the mitochondrial outer membrane triggers MOMP, leading to the release of cytochrome c and other pro-apoptotic factors. 3. **Caspase independence of initiation:** TNFRSF21-induced apoptosis does not require caspase-8 or Bid activation. The pathway proceeds directly from receptor activation to mitochondrial dysfunction, bypassing the canonical Type I (death receptor) and Type II (mitochondrial amplification) pathways. 4. **Caspase-9 dependence:** The downstream execution phase requires caspase-9 activation through the apoptosome complex, followed by effector caspase-3 activation. 5. **Bcl-2 inhibition:** Overexpression of anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-XL) can inhibit TNFRSF21-induced apoptosis, confirming the mitochondrial dependence of this pathway. ### 3.3 Necroptosis Regulation Beyond apoptosis, TNFRSF21 has been implicated in the regulation of necroptosis, a form of programmed necrosis mediated by RIPK1/RIPK3/MLKL signaling. Several studies have identified TNFRSF21 as a component of necroptosis-related gene signatures with prognostic significance in various cancers. In osteosarcoma, TNFRSF21 was identified as an inhibitory factor based on necroptosis-related prognostic gene signatures, with higher expression correlating with worse overall survival. Similarly, necroptosis-related signatures incorporating TNFRSF21 have been developed for skin cutaneous melanoma, bladder cancer, and ovarian cancer. The mechanistic link between TNFRSF21 and necroptosis may involve: - **RIPK1 recruitment:** The TNFRSF21 death domain can interact with RIPK1, potentially channeling signals toward necroptotic pathways when caspase-8 is inhibited. - **ROS generation:** TNFRSF21 signaling can induce reactive oxygen species production, which is a common trigger for necroptosis. - **Cross-talk with TNFR1:** TNFRSF21 may modulate TNFR1 signaling complexes, shifting the balance between apoptosis, necroptosis, and survival. ### 3.4 Non-Apoptotic Signaling: NF-κB and MAPK Pathways In addition to cell death induction, TNFRSF21 can activate pro-survival and pro-inflammatory signaling pathways: **NF-κB pathway:** TNFRSF21 engagement leads to the recruitment of TRAF2 and TRAF5 to the juxtamembrane region, followed by activation of the IKK complex and subsequent phosphorylation and degradation of IκBα. This results in nuclear translocation of NF-κB (p50/p65 heterodimers) and transcription of target genes including pro-inflammatory cytokines, anti-apoptotic factors (Bcl-XL, cIAPs), and adhesion molecules. **ERK/FOXM1 pathway:** In lung cancer cells, aberrant upregulation of TNFRSF21 enhances tumor aggressiveness through activation of the ERK/FOXM1 signaling cascade. Mechanistically, TNFRSF21 activates MEK1/2, which phosphorylates ERK1/2. Activated ERK then phosphorylates and stabilizes FOXM1, a transcription factor that drives expression of genes involved in cell cycle progression (Cyclin B1, Cdc25B), invasion (MMP-2, MMP-9), and stemness (SOX2, OCT4). **PI3K/AKT pathway:** TNFRSF21 can activate PI3K, leading to AKT phosphorylation at T308 and S473. AKT activation promotes cell survival through phosphorylation of Bad, Forkhead transcription factors, and MDM2, and stimulates cell growth through mTORC1 activation. **JNK pathway:** TNFRSF21 engagement activates JNK through TRAF2-mediated activation of ASK1 or MEKK1. JNK can phosphorylate c-Jun, ATF2, and other transcription factors, contributing to inflammatory gene expression. ### 3.5 Regulation of Angiogenesis and Vascular Development TNFRSF21 plays a critical role in central nervous system (CNS) angiogenesis and blood-brain barrier (BBB) formation. Studies using gene expression profiling of mouse vasculature identified DR6/TNFRSF21 and TROY/TNFRSF19 as regulators of CNS-specific angiogenesis. TNFRSF21 expression is enriched in endothelial cells of the developing CNS vasculature, where it regulates: - **Endothelial cell proliferation:** TNFRSF21 signaling modulates endothelial cell cycle progression, balancing proliferation and quiescence. - **Vessel branching:** TNFRSF21 influences the branching morphogenesis of CNS blood vessels, ensuring proper vascular network formation. - **BBB integrity:** TNFRSF21 contributes to the establishment and maintenance of tight junctions between brain endothelial cells, a critical component of the BBB. In the context of diabetes, TNFRSF21 expression is altered in retinal and brain microvasculature, suggesting that dysregulated TNFRSF21 signaling may contribute to diabetic microvascular complications. ### 3.6 Immune Regulation and Inflammation TNFRSF21 is expressed on multiple immune cell types, including T cells, B cells, monocytes, and dendritic cells, where it modulates immune responses: - **T cell regulation:** TNFRSF21 can induce apoptosis in activated T cells, contributing to the contraction phase of immune responses and the maintenance of peripheral tolerance. In allergic asthma, rare variants in TNFRSF21 are associated with disease development, suggesting a role in regulating airway inflammation. - **B cell function:** TNFRSF21 is highly expressed on germinal center B cells and may regulate B cell selection and antibody affinity maturation. In EBV-associated diffuse large B-cell lymphoma, TNFRSF21 mutations have been identified, implicating the receptor in B-cell lymphomagenesis. - **Monocyte/macrophage regulation:** TNFRSF21 expression on monocytes influences their differentiation and inflammatory cytokine production. In bovine mastitis, TNFRSF21 was identified as a susceptibility gene, with expression levels correlating with disease severity. - **Mucosal immunity:** TNFRSF21 orchestrates epithelial keratinization and tight junction integrity in oral mucosa, playing a critical role in periodontal tissue repair. In periodontitis, TNFRSF21 expression is dysregulated, contributing to epithelial barrier disruption and disease progression. ### 3.7 Protein-Protein Interaction Network The TNFRSF21 interactome includes both direct binding partners and components of downstream signaling complexes: | **Interactor** | **Interaction Type** | **Functional Consequence** | **Reference** | |---|---|---|---| | Bax | Direct (death domain) | Mitochondrial apoptosis | | | TRAF2 | Direct (juxtamembrane) | NF-κB and JNK activation | | | TRAF5 | Direct (juxtamembrane) | NF-κB activation | | | RIPK1 | Direct (death domain) | Necroptosis signaling | | | APP | Direct (extracellular) | Neuronal apoptosis | | | TRADD | Indirect | Apoptosis signaling | | | FADD | Indirect | Caspase-8 recruitment (minor) | | | IRE1 | Indirect (ER stress) | Regulation of TNFRSF21 expression | | | eEF1A1 | Indirect | Regulation of alternative splicing | | STRING database analysis reveals that TNFRSF21 is part of a densely connected network centered on TNFRSF1A, TNFRSF1B, and TNFRSF19, with functional links to downstream effectors including TRADD, TRAF2, and RIPK1. ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 High Myopia-Associated Mutations TNFRSF21 was identified as a causative gene for high myopia (HM) through whole-exome sequencing of affected families. Subsequent studies in cohorts of early-onset high myopia (eo-HM) patients have confirmed the contribution of TNFRSF21 mutations to this condition. | **Variant** | **Protein Change** | **Variant Type** | **Clinical Significance** | **Reference** | |---|---|---|---|---| | c.1174C>T | p.Arg392Trp | Missense | Pathogenic (HM) | | | c.1532G>A | p.Arg511Gln | Missense | Pathogenic (HM) | | | c.1756C>T | p.Arg586Trp | Missense | Likely pathogenic (HM) | | | c.1987G>A | p.Val663Met | Missense | Uncertain significance | | | c.2215C>T | p.Arg739Trp | Missense | Uncertain significance | | The pathogenic mutations cluster in the cytoplasmic domain, particularly within and adjacent to the death domain (aa 430-520). The p.Arg392Trp mutation is located in the juxtamembrane region and may disrupt TRAF binding, while p.Arg511Gln and p.Arg586Trp are within the death domain and likely impair Bax interaction or downstream signaling. Functional studies demonstrate that these mutations reduce TNFRSF21-induced apoptosis in retinal pigment epithelial cells, suggesting that impaired apoptosis during ocular development leads to abnormal scleral remodeling and axial elongation characteristic of high myopia. ### 4.2 Allergic Asthma-Associated Variants Gene-based association studies of rare variants in children of diverse ancestries have implicated TNFRSF21 in the development of allergic asthma. The study identified multiple rare coding variants that collectively contribute to asthma susceptibility: - **p.Val145Met (c.433G>A):** Located in CRD2, the primary ligand-binding domain. This variant may alter ligand recognition or receptor activation. - **p.Thr245Ala (c.733A>G):** Located in the mucin-like stalk region, potentially affecting O-glycosylation and receptor conformation. - **p.Leu378Phe (c.1132C>T):** Located in the juxtamembrane region, near the TRAF-binding motif. These variants are associated with increased airway hyperresponsiveness and elevated IgE levels, suggesting that TNFRSF21 signaling modulates type 2 immune responses in the airways. Additionally, TNFRSF21 expression is altered in corticosteroid-resistant asthma, implicating the receptor in treatment response variability. ### 4.3 Cancer-Associated Mutations and Expression Alterations TNFRSF21 exhibits complex, context-dependent roles in cancer, functioning as either a tumor suppressor (through apoptosis induction) or an oncogene (through activation of survival and proliferation pathways). **Tumor suppressor context:** - **Head and neck squamous cell carcinoma (HNSCC):** miR-20a-5p directly targets TNFRSF21, and its upregulation in HNSCC leads to reduced TNFRSF21 expression, promoting cell proliferation and invasion. - **Lung adenocarcinoma:** The lncRNA MIR31HG/miR-193a-3p/TNFRSF21 regulatory axis modulates cuproptosis and tumor progression. - **Gastric cancer:** TNFRSF21 is among the genes regulated by the tumor suppressor FHIT through translational mechanisms. **Oncogenic context:** - **Lung cancer:** Aberrant upregulation of TNFRSF21 enhances tumor aggressiveness via activation of the ERK/FOXM1 signaling cascade. - **Osteosarcoma:** TNFRSF21 is identified as an inhibitory factor in necroptosis-related prognostic signatures, with high expression correlating with poor prognosis. - **Melanoma:** TNFRSF21 is included in multiple prognostic signatures (necroptosis-related, cuproptosis-related, angiogenesis-related) and is associated with immune infiltration and treatment response. - **Breast cancer:** TNFRSF21 expression is altered in response to various therapeutic agents, including oleuropein, sanguinarine, and BP-C1, suggesting a role in drug sensitivity. **Somatic mutations in cancer:** Whole-genome and targeted amplicon sequencing of EBV-associated diffuse large B-cell lymphoma identified recurrent TNFRSF21 mutations, including both missense and truncating variants. These mutations may disrupt the tumor suppressor function of TNFRSF21, contributing to lymphomagenesis. ### 4.4 Other Disease Associations - **Endometriosis and Hashimoto disease:** TNFRSF21 shows differential expression in both conditions, suggesting shared molecular mechanisms. - **Recurrent pregnancy loss:** RNA sequencing of decidua identified TNFRSF21 as differentially expressed in recurrent pregnancy loss, implicating the receptor in placental development and maintenance. - **Periodontitis:** TNFRSF21 orchestrates epithelial keratinization and tight junction integrity in oral mucosal repair, with dysregulated expression contributing to disease progression. - **Alcoholic hepatitis:** TNFRSF21 is among the key genes identified in integrated network analysis of alcoholic hepatitis, linking the receptor to alcohol-induced liver injury. - **Bipolar disorder:** Soluble TNFRSF21 levels are altered in cerebrospinal fluid of bipolar disorder patients, suggesting a role in neuropsychiatric pathology. - **Alzheimer's disease:** TNFRSF21 interacts with APP and is implicated in neurodegeneration, with expression changes observed in single neurons throughout Alzheimer's disease pathological progression. - **Atherosclerosis:** TNFRSF21 is among the ferroptosis and necroptosis-related genes shared between psoriasis and atherosclerosis, suggesting a common inflammatory mechanism. - **Bovine mastitis:** TNFRSF21 is involved in the regulation of mastitis susceptibility through GWAS and post-transcriptional analysis. ### 4.5 Clinical Differential Diagnosis When TNFRSF21 mutations are suspected, the following clinical presentations warrant genetic testing: 1. **High myopia:** Patients with early-onset (before age 10) high myopia (spherical equivalent ≤ -6.00 D) and no other syndromic features should be screened for TNFRSF21 mutations, particularly if there is a family history consistent with autosomal dominant inheritance. 2. **Allergic asthma:** Children with severe, early-onset allergic asthma and a family history of atopy may carry rare TNFRSF21 variants. Genetic testing may be considered in research settings or for patients with unexplained corticosteroid resistance. 3. **Cancer predisposition:** While TNFRSF21 mutations are not currently included in standard cancer predisposition panels, patients with a personal or family history of EBV-associated DLBCL and other B-cell lymphomas may benefit from research-based sequencing. 4. **Periodontitis:** Patients with aggressive periodontitis and impaired mucosal healing may have altered TNFRSF21 expression, though germline mutations have not been systematically evaluated in this context. ## 5. Host-Pathogen & Viral Interactions ### 5.1 Epstein-Barr Virus (EBV) EBV-associated diffuse large B-cell lymphoma (DLBCL) exhibits recurrent TNFRSF21 mutations, suggesting that the virus may exploit TNFRSF21 signaling for B-cell transformation. The proposed mechanisms include: - **Latent membrane protein 1 (LMP1):** EBV LMP1 constitutively activates NF-κB signaling and may modulate TNFRSF21 expression through shared downstream pathways. LMP1 can also induce TNFRSF21 expression, potentially contributing to the survival of latently infected B cells. - **EBV nuclear antigens (EBNAs):** EBNA2 and EBNA3 proteins can modulate host gene expression through epigenetic mechanisms, potentially affecting TNFRSF21 promoter methylation and expression. - **Mutation selection:** The presence of TNFRSF21 mutations in EBV-associated DLBCL suggests that inactivation of TNFRSF21-mediated apoptosis provides a survival advantage to EBV-transformed B cells, allowing them to escape cell death checkpoints. ### 5.2 Chandipura Virus (CHPV) Chandipura virus, a neurotropic virus causing encephalitis, alters the cellular miRNome in human microglial cells, with downstream effects on TNFRSF21 expression. CHPV infection induces changes in multiple miRNAs that target TNFRSF21, potentially modulating the apoptotic response of microglial cells to viral infection. ### 5.3 Fowl Adenovirus Serotype 4 (FAdV-4) Transcriptome analysis of Leghorn male hepatocellular cells infected with FAdV-4 revealed altered expression of TNFRSF21, suggesting that the receptor may be involved in the host response to adenoviral infection. The virus may modulate TNFRSF21 signaling to evade apoptosis and promote viral replication. ### 5.4 Aleutian Mink Disease Virus (AMDV) Selection signature analysis in Aleutian mink disease identified TNFRSF21 as one of the genes associated with disease susceptibility. AMDV is a persistent viral infection that causes immune dysregulation, and TNFRSF21 may contribute to the apoptotic loss of infected cells or the dysregulated immune response characteristic of the disease. ### 5.5 SARS-CoV-2 and COVID-19 Pathogenetic profiling of COVID-19 and SARS-like viruses identified TNFRSF21 among the genes potentially involved in the host response to coronavirus infection. The receptor's role in regulating apoptosis and inflammation may contribute to the cytokine storm and tissue damage observed in severe COVID-19. ### 5.6 Avian Leukosis Virus (ALV-J) Transcriptional analysis of CD4+CD8+ double-positive T cells from ALV-J infected chickens revealed differential expression of TNFRSF21, suggesting a role in the antiviral T cell response. ### 5.7 Bacterial Pathogens In the context of bacterial infections, TNFRSF21 expression is modulated in response to lipopolysaccharide (LPS) stimulation. Studies in chondrocytes demonstrated that exosomes derived from miRNA-210-overexpressing bone marrow mesenchymal stem cells protect against LPS-induced injury through modulation of the NF-κB pathway, which may involve TNFRSF21. Additionally, TNFRSF21 is implicated in the host response to bacterial mastitis in cattle. ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Therapeutic Targeting Strategies TNFRSF21 represents an attractive therapeutic target given its involvement in multiple disease processes. Several strategies are being explored: **Monoclonal Antibodies:** - **Agonistic antibodies:** Antibodies that crosslink TNFRSF21 and activate apoptotic signaling could be used to eliminate cancer cells. Preclinical studies have demonstrated that anti-DR6 antibodies can induce apoptosis in tumor cell lines expressing high levels of TNFRSF21. - **Antagonistic antibodies:** Blocking antibodies that prevent ligand binding or receptor clustering could be used to inhibit TNFRSF21-mediated inflammation or neurodegeneration. - **Antibody-drug conjugates (ADCs):** TNFRSF21-directed ADCs could deliver cytotoxic payloads specifically to TNFRSF21-expressing tumor cells. **Soluble Decoy Receptors:** - Recombinant soluble TNFRSF21 extracellular domain (sDR6) could be administered to sequester ligands and prevent membrane-bound receptor activation. This approach may be beneficial in conditions where TNFRSF21 signaling drives pathology. **Small-Molecule Inhibitors:** - Compounds that disrupt the TNFRSF21-Bax interaction could block TNFRSF21-induced apoptosis, potentially useful in neurodegenerative conditions where excessive apoptosis occurs. - Inhibitors of the TNFRSF21-ERK/FOXM1 pathway could be used to treat cancers where TNFRSF21 promotes tumor aggressiveness. **Gene Therapy:** - AAV-mediated delivery of TNFRSF21 shRNA or CRISPR-based gene editing could be used to knockdown or correct mutant TNFRSF21 alleles in diseases where loss-of-function mutations cause pathology (e.g., high myopia). **Epigenetic Modulators:** - Given that TNFRSF21 expression is regulated by promoter methylation, DNA methyltransferase inhibitors (e.g., 5-azacytidine, decitabine) could be used to reactivate silenced TNFRSF21 expression in cancers where it functions as a tumor suppressor. ### 6.2 Existing Drugs Affecting TNFRSF21 Expression Several approved drugs have been shown to modulate TNFRSF21 expression, which may contribute to their therapeutic effects: | **Drug** | **Class** | **Effect on TNFRSF21** | **Disease Context** | **Reference** | |---|---|---|---|---| | Fludarabine | Purine analog | Alters apoptotic gene expression including TNFRSF ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)